The emerging role of IGF-1 deficiency in cardiovascular aging: Recent advances

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 67 A, Issue 6, 2012, Pages 599-610

  Ungvari, Zoltan ^a   Csiszar, Anna ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; Endothelial dysfunction; Myocardial infarction; Vascular aging; Vascular dementia

Indexed keywords

ANIMALIA;

SOMATOMEDIN C; TRANSCRIPTION FACTOR NRF2;

AGING; ANIMAL; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DISEASE MODEL; FEMALE; HEART FAILURE; HUMAN; LARON SYNDROME; MALE; METABOLISM; MICROVASCULATURE; MOUSE; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW;

AGING; ANIMALS; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; MALE; MICE; MICROVESSELS; NF-E2-RELATED FACTOR 2; PARACRINE COMMUNICATION; RATS;

EID: 84861087862     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls072     Document Type: Review

References (151)

1. Higashi Y, Sukhanov S, Shai SY, Delafontaine P. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci. 2012. In press.
2. Novosyadlyy R, LeRoith D. Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci. 2012. In press.
3. Sonntag WE, Csiszar A, de Cabo R, Ferrucci L, Ungvari Z. IGF-1, growth hormone and mammalian aging: controversies and progress toward understanding the diverse actions of anabolic hormones during the lifespan. J Gerontol A Biol Sci Med Sci. 2012. In press.
4. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am J Physiol Endocrinol Metab. 2004;286:E896-E901. (Pubitemid 38668810)
5. Chisalita SI, Johansson GS, Liefvendahl E, Back K, Arnqvist HJ. Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. J Mol Endocrinol. 2009;43:231-239.
6. Johansson GS, Chisalita SI, Arnqvist HJ. Human microvascular endothelial cells are sensitive to IGF-I but resistant to insulin at the receptor level. Mol Cell Endocrinol. 2008;296:58-63.
7. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65:1028-1041.
8. Breese CR, Ingram RL, Sonntag WE. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J Gerontol. 1991;46:B180-B187.
9. D'Costa AP, Ingram RL, Lenham JE, Sonntag WE. The regulation and mechanisms of action of growth hormone and insulin-like growth factor 1 during normal ageing. J Reprod Fertil. 1993;46:87-98.
10. Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res. 2002;54:25-35.
11. Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol. 1999;50:457-464. (Pubitemid 29193228)
12. Denti L, Annoni V, Cattadori E, et al. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med. 2004;117:312-317. (Pubitemid 39164563)
13. Oflaz H, Sen F, Elitok A, et al. Coronary flow reserve is impaired in patients with adult growth hormone (GH) deficiency. Clin Endocrinol. 2007;66:524-529. (Pubitemid 46434934)
14. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-288. (Pubitemid 20229130)
15. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996;81:1169-1172. (Pubitemid 26083989)
16. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997;46:75-81. (Pubitemid 27072849)
17. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425-431. (Pubitemid 32156141)
18. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139:642-648.
19. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004;89:114-120. (Pubitemid 38183869)
20. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation. 2004;110:2260-2265. (Pubitemid 39372511)
21. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol. 1996;77:200-202.
22. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944. (Pubitemid 34925327)
23. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001;38:26-32. (Pubitemid 32613824)
24. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25-31. (Pubitemid 36043733)
25. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol. 2002;56:493-501. (Pubitemid 34429624)
26. Evans LM, Davies JS, Anderson RA, et al. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol. 2000;142:254-262.
27. Galderisi M, Caso P, Cicala S, et al. Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens. 2002;15:766-772. (Pubitemid 34970104)
28. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I,-II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005;90:5937-5941. (Pubitemid 41606508)
29. De Smedt A, Brouns R, Uyttenboogaart M, et al. Insulin-like growth factor I serum levels influence ischemic stroke outcome. Stroke. 2011;42:2180-2185.
30. Aberg D, Jood K, Blomstrand C, et al. Serum IGF-I levels correlate to improvement of functional outcome after ischemic stroke. J Clin Endocrinol Metab. 2011;96:E1055-E1064.
31. Zhu W, Fan Y, Hao Q, et al. Postischemic IGF-1 gene transfer promotes neurovascular regeneration after experimental stroke. J Cereb Blood Flow Metab. 2009;29:1528-1537.
32. Laron Z, Klinger B, Silbergeld A. Patients with Laron syndrome have Osteopenia/Osteoporosis. J Bone Miner Res. 1999;14:156-157. (Pubitemid 29021619)
33. Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol. 2000;85:209-213. (Pubitemid 30026104)
34. Feinberg MS, Scheinowitz M, Laron Z. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. Am Heart J. 2003;145:549-553. (Pubitemid 36390504)
35. Scheinowitz M, Feinberg MS, Laron Z. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function. Growth Horm IGF Res. 2009;19:280-282.
36. Ben-Dov I, Gaides M, Scheinowitz M, Wagner R, Laron Z. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol (Oxf). 2003;59:763-767. (Pubitemid 37491581)
37. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism. 1996;45:1263-1266. (Pubitemid 26337673)
38. Shechter M, Ginsberg S, Scheinowitz M, Feinberg MS, Laron Z. Obese adults with primary growth hormone resistance (Laron syndrome) have normal endothelial function. Growth Horm IGF Res. 2007;17:165-170. (Pubitemid 46523780)
39. Amemiya T, Toibana M, Hashimoto M, Oseko F, Imura H. Diabetic retinopathy in acromegaly. Ophthalmologica. 1978;176:74-80. (Pubitemid 8280795)
40. Inokuchi N, Ikeda T, Yasuda F, Shirai S, Uchinori Y. Severe proliferative diabetic retinopathy associated with acromegaly. Br J Ophthalmol. 1999;83:629-630. (Pubitemid 29213145)
41. Tran HA, Petrovsky N, Field AJ. Severe diabetic retinopathy: a rare complication of acromegaly. Intern Med J. 2002;32:52-54. (Pubitemid 36124640)
42. Dominici FP, Hauck S, Argentino DP, Bartke A, Turyn D. Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice. J Endocrinol. 2002;173:81-94. (Pubitemid 34428894)
43. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:70ra13.
44. Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol. 2004;151:103-106. (Pubitemid 39117370)
45. Nieves-Martinez E, Sonntag WE, Wilson A, et al. Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation. J Endocrinol. 2010;204:31-36.
46. Ramsey MM, Ingram RL, Cashion AB, et al. Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinology. 2002;143:4139-4142. (Pubitemid 35244394)
47. Sonntag WE, Carter CS, Ikeno Y, et al. Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology. 2005;146:2920-2932. (Pubitemid 41002799)
48. Ungvari Z, Gautam T, Koncz P, et al. Vasoprotective effects of life span-extending peripubertal GH replacement in Lewis Dwarf rats. J Gerontol A Biol Sci Med Sci. 2010;65:1145-1156.
49. Ungvari Z, Sosnowska D, Podlutsky A, Koncz P, Sonntag WE, Csiszar A. Free radical production, antioxidant capacity, and oxidative stress response signatures in fibroblasts from Lewis dwarf rats: effects of life span-extending peripubertal GH treatment. J Gerontol A Biol Sci Med Sci. 2011;66:501-510.
50. Bailey-Downs LC, Sosnowska D, Toth P, et al. High-fat diet-induced endothelial impairment in obese Lewis Dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci. 2011. doi:10.1093/gerona/glr197
51. Cittadini A, Stromer H, Vatner DE, et al. Consequences of growth hormone deficiency on cardiac structure, function, and beta-adrenergic pathway: studies in mutant dwarf rats. Endocrinology. 1997;138:5161-5169. (Pubitemid 27509673)
52. Longobardi S, Cittadini A, Stromer H, et al. Echocardiographic assessment of cardiac morphology and function in mutant dwarf rats. Growth Horm IGF Res. 2000;10:242-247.
53. Stromer H, Cittadini A, Grossman JD, Douglas PS, Morgan JP. Intrinsic cardiac muscle function, calcium handling and beta-adrenergic responsiveness is impaired in rats with growth hormone deficiency. Growth Horm IGF Res. 1999;9:262-271. (Pubitemid 29499867)
54. Groban L, Lin M, Kassik KA, Ingram RL, Sonntag WE. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Horm IGF Res. 2011;21:81-88.
55. Cittadini A, Grossman JD, Stromer H, Katz SE, Morgan JP, Douglas PS. Importance of an intact growth hormone/insulin-like growth factor 1 axis for normal post-infarction healing: studies in dwarf rats. Endocrinology. 2001;142:332-338. (Pubitemid 32183694)
56. Beznak M. The effect of adrenocortical hormones alone and in combination with growth hormone on cardiac hypertrophy and blood pressure of hypophysectomized rats. J Physiol. 1954;124:75-83.
57. Beznak M. The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone. J Physiol. 1954;124:64-74.
58. Beznak M. The effect of the pituitary and growth hormone on the blood pressure and on the ability of the heart to hypertrophy. J Physiol. 1952;116:74-83.
59. Csiszar A, Labinskyy N, Perez V, et al. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol. 2008;295:H1882-H1894.
60. van Buul-Offers S, Smeets T, Van den Brande JL. Effects of growth hormone and thyroxine on the relation between tibial length and the histological appearance of the proximal tibial epiphysis in Snell dwarf mice. Growth. 1984;48:166-175. (Pubitemid 14030386)
61. Helms SA, Azhar G, Zuo C, Theus SA, Bartke A, Wei JY. Smaller cardiac cell size and reduced extra-cellular collagen might be beneficial for hearts of Ames dwarf mice. Int J Biol Sci. 2010;6:475-490.
62. Ren J, Brown-Borg HM. Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency. Growth Horm IGF Res. 2002;12:99-105. (Pubitemid 37337008)
63. Bokov AF, Lindsey ML, Khodr C, Sabia MR, Richardson A. Long-lived ames dwarf mice are resistant to chemical stressors. J Gerontol A Biol Sci Med Sci. 2009;64:819-827.
64. Choksi KB, Nuss JE, DeFord JH, Papaconstantinou J. Mitochondrial electron transport chain functions in long-lived Ames dwarf mice. Aging (Albany NY). 2011;3:754-767.
65. Reddy AK, Amador-Noguez D, Darlington GJ, et al. Cardiac function in young and old Little mice. J Gerontol A Biol Sci Med Sci. 2007;62:1319-1325. (Pubitemid 351158360)
66. Bailey-Downs LC, Mitschelen M, Sosnowska D, et al. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci. 2011. doi:10.1093/gerona/glr164
67. Mitschelen M, Yan H, Farley JA, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience. 2011;185:50-60.
68. Li Q, Ceylan-Isik AF, Li J, Ren J. Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res. 2008;11:725-733.
69. Hua Y, Zhang Y, Ren J. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Cell Mol Med. 2012;16:83-95.
70. Yu R, Yakar S, Liu YL, et al. Liver-specific IGF-I gene deficient mice exhibit accelerated diabetes in response to streptozotocin, associated with early onset of insulin resistance. Mol Cell Endocrinol. 2003;204:31-42. (Pubitemid 36871550)
71. Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60:2169-2178.
72. Laustsen PG, Russell SJ, Cui L, et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol. 2007;27:1649-1664.
73. Sun LY, Al-Regaiey K, Masternak MM, Wang J, Bartke A. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol Aging. 2005;26:929-937. (Pubitemid 40249496)
74. Wang J, Niu W, Nikiforov Y, et al. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest. 1997;100:1425-1439. (Pubitemid 27425767)
75. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab. 2010;21:245-254.
76. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/-mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol. 2010;30:1916-1924.
77. Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2684-2690. (Pubitemid 350158923)
78. Conover CA, Bale LK, Mader JR, Mason MA, Keenan KP, Marler RJ. Longevity and age-related pathology of mice deficient in pregnancy-associated plasma protein-A. J Gerontol A Biol Sci Med Sci. 2010;65:590-599.
79. Louis A, Bartke A, Masternak MM. Effects of growth hormone and thyroxine replacement therapy on insulin signaling in Ames dwarf mice. J Gerontol A Biol Sci Med Sci. 2010;65:344-352.
80. Masternak MM, Panici JA, Wang F, Wang Z, Spong A. The effects of growth hormone (GH) treatment on GH and insulin/IGF-1 signaling in long-lived Ames dwarf mice. J Gerontol A Biol Sci Med Sci. 2010;65:24-30.
81. Panici JA, Wang F, Bonkowski MS, et al. Is altered expression of hepatic insulin-related genes in growth hormone receptor knockout mice due to GH resistance or a difference in biological life spans? J Gerontol A Biol Sci Med Sci. 2009;64:1126-1133.
82. Santini MP, Lexow J, Borsellino G, et al. IGF-1Ea induces vessel formation after injury and mediates bone marrow and heart cross-talk through the expression of specific cytokines. Biochem Biophys Res Commun. 2011;410:201-207.
83. Vinciguerra M, Santini MP, Claycomb WC, Ladurner AG, Rosenthal N. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging (Albany NY). 2010;2:43-62.
84. Vinciguerra M, Santini MP, Martinez C, et al. mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart. Aging Cell. 2012;11:139-149.
85. Leri A, Kajstura J, Li B, et al. Cardiomyocyte aging is gender-dependent: the local IGF-1-IGF-1R system. Heart Dis. 2000;2:108-115.
86. Sonntag WE, Lynch CD, Cooney PT, Hutchins PM. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology. 1997;138:3515-3520. (Pubitemid 27345707)
87. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, et al. Caloric restriction and growth hormone receptor knockout: effects on expression of genes involved in insulin action in the heart. Exp Gerontol. 2006;41:417-429.
88. D'Costa AP, Lenham JE, Ingram RL, Sonntag WE. Moderate caloric restriction increases type 1 IGF receptors and protein synthesis in aging rats. Mech Ageing Dev. 1993;71:59-71.
89. Groban L, Pailes NA, Bennett CD, et al. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci. 2006;61:28-35. (Pubitemid 43227799)
90. Li Q, Wu S, Li SY, et al. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am J Physiol. 2007;292:H1398-H1403. (Pubitemid 46377127)
91. Li Q, Ren J. Influence of cardiac-specific overexpression of insulin-like growth factor 1 on lifespan and aging-associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expression. Aging Cell. 2007;6:799-806. (Pubitemid 350131048)
92. Ren J, Duan J, Thomas DP, et al. IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol. 2008;294:R793-R802. (Pubitemid 351346955)
93. Paolisso G, Ammendola S, Del Buono A, et al. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab. 1997;82:2204-2209. (Pubitemid 27287585)
94. Padin-Iruegas ME, Misao Y, Davis ME, et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation. 2009;120:876-887.
95. Urbanek K, Rota M, Cascapera S, et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res. 2005;97:663-673. (Pubitemid 41416335)
96. Torella D, Rota M, Nurzynska D, et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res. 2004;94:514-524. (Pubitemid 38326287)
97. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100:1991-1999. (Pubitemid 27459352)
98. Leri A, Liu Y, Wang X, et al. Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res. 1999;84:752-762. (Pubitemid 29181482)
99. Li B, Setoguchi M, Wang X, et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res. 1999;84:1007-1019. (Pubitemid 29227680)
100. D'Amario D, Cabral-Da-Silva MC, Zheng H, et al. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. Circ Res. 2011;108:1467-1481.
101. Anversa P, Li P, Sonnenblick EH, Olivetti G. Effects of aging on quantitative structural properties of coronary vasculature and microvasculature in rats. Am J Physiol. 1994;267:H1062-H1073. (Pubitemid 24299056)
102. Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis. 2001;37:601-611. (Pubitemid 32195301)
103. Montagna W, Carlisle K. Structural changes in aging human skin. J Invest Dermatol. 1979;73:47-53. (Pubitemid 10136108)
104. Riddle DR, Sonntag WE, Lichtenwalner RJ. Microvascular plasticity in aging. Ageing Res Rev. 2003;2:149-168. (Pubitemid 37443910)
105. Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing. J Anat. 2000;197(Pt 4):575-585. (Pubitemid 32051538)
106. Hua K, Forbes ME, Lichtenwalner RJ, Sonntag WE, Riddle DR. Adult-onset deficiency in growth hormone and insulin-like growth factor-I alters oligodendrocyte turnover in the corpus callosum. Glia. 2008.
107. Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev. 2005;4:195-212. (Pubitemid 41111978)
108. Ramsey MM, Weiner JL, Moore TP, Carter CS, Sonntag WE. Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning. Neuroscience. 2004;129:119-127. (Pubitemid 39360948)
109. Poe BH, Linville C, Riddle DR, Sonntag WE, Brunso-Bechtold JK. Effects of age and insulin-like growth factor-1 on neuron and synapse numbers in area CA3 of hippocampus. Neuroscience. 2001;107:231-238. (Pubitemid 33145345)
110. Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience. 2001;107:603-613. (Pubitemid 33097497)
111. Lopez-Lopez C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci USA. 2004;101:9833-9838. (Pubitemid 38869322)
112. Khan AS, Lynch CD, Sane DC, Willingham MC, Sonntag WE. Growth hormone increases regional coronary blood flow and capillary density in aged rats. J Gerontol Biol Sci. 2001;56:B364-B371. (Pubitemid 32717783)
113. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol Genomics. 2004;17:21-30. (Pubitemid 38924147)
114. Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z. Vasculoprotective effects of anti-TNF-alpha treatment in aging. Am J Pathol. 2007;170:388-398. (Pubitemid 47339216)
115. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157-168.
116. Asai K, Kudej RK, Shen YT, et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol. 2000;20:1493-1499. (Pubitemid 30353879)
117. Li Y, Wu H, Khardori R, Song YH, Lu YW, Geng YJ. Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem Biophys Res Commun. 2009;384:259-264.
118. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation. 1999;99:111-120. (Pubitemid 29035965)
119. Guan J, Bennet L, George S, et al. Insulin-like growth factor-1 reduces postischemic white matter injury in fetal sheep. J Cereb Blood Flow Metab. 2001;21:493-502. (Pubitemid 32422869)
120. Guan J, Bennet TL, George S, et al. Selective neuroprotective effects with insulin-like growth factor-1 in phenotypic striatal neurons following ischemic brain injury in fetal sheep. Neuroscience. 2000;95:831-839.
121. Leinninger GM, Feldman EL. Insulin-like growth factors in the treatment of neurological disease. Endocr Dev. 2005;9:135-159.
122. Loddick SA, Liu XJ, Lu ZX, et al. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci USA. 1998;95:1894-1898. (Pubitemid 28103490)
123. Mackay KB, Loddick SA, Naeve GS, Vana AM, Verge GM, Foster AC. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab. 2003;23:1160-1167. (Pubitemid 37229519)
124. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001;187:91-97. (Pubitemid 32618661)
125. Schabitz WR, Hoffmann TT, Heiland S, et al. Delayed neuroprotective effect of insulin-like growth factor-i after experimental transient focal cerebral ischemia monitored with mri. Stroke. 2001;32:1226-1233. (Pubitemid 32825815)
126. Zhu W, Fan Y, Frenzel T, et al. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke. 2008;39:1254-1261. (Pubitemid 351440699)
127. Thum T, Hoeber S, Froese S, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res. 2007;100:434-443.
128. Zhu G, Song M, Wang H, et al. Young environment reverses the declined activity of aged rat-derived endothelial progenitor cells: involvement of the phosphatidylinositol 3-kinase/Akt signaling pathway. Ann Vasc Surg. 2009;23:519-534.
129. Forman K, Vara E, Garcia C, et al. Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice. J Gerontol A Biol Sci Med Sci. 2011;66:823-834.
130. Csiszar A, Ungvari Z, Edwards JG, et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002;90:1159-1166. (Pubitemid 34786900)
131. Kubis N, Besnard S, Silvestre JS, et al. Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens. 2002;20:273-280. (Pubitemid 34913792)
132. Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol. 2005;289:R307-R316. (Pubitemid 41060480)
133. Pu XY, Wang XH, Gao WC, et al. Insulin-like growth factor-1 restores erectile function in aged rats: modulation the integrity of smooth muscle and nitric oxide-cyclic guanosine monophosphate signaling activity. J Sex Med. 2008;5:1345-1354.
134. Cittadini A, Monti MG, Castiello MC, et al. Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury. J Thromb Haemost. 2009;7:1920-1928.
135. Pearson KJ, Lewis KN, Price NL, et al. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci USA. 2008;105:2325-2330. (Pubitemid 351520512)
136. Suh JH, Shenvi SV, Dixon BM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004;101:3381-3386. (Pubitemid 38338203)
137. Tullet JM, Hertweck M, An JH, et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell. 2008;132:1025-1038. (Pubitemid 351391953)
138. Ungvari ZI, Bailey-Downs L, Gautam T, et al. Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am J Physiol Heart Circ Physiol. 2011;300:H1133-H1140.
139. Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010;299:H18-H24.
140. Ungvari Z, Parrado-Fernandez C, Csiszar A, de Cabo R. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res. 2008;102:519-528.
141. Ungvari Z, Bailey-Downs L, Gautam T, et al. Age-associated vascular oxidative stress, Nrf2 dysfunction and NF-kB activation in the non-human primate Macaca mulatta. J Gerontol A Biol Sci Med Sci. 2011;66:866-875.
142. Collins AR, Lyon CJ, Xia X, et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res. 2009;104:e42-e54.
143. Ungvari Z, Bailey-Downs L, Sosnowska D, et al. Vascular oxidative stress in aging: a homeostatic failure due to dysregulation of Nrf2-mediated antioxidant response. Am J Physiol. 2011;301:H363-H372.
144. Morrison CD, Pistell PJ, Ingram DK, et al. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J Neurochem. 2010;114:1581-1589.
145. Xu J, Rong S, Xie B, et al. Procyanidins extracted from the lotus seedpod ameliorate age-related antioxidant deficit in aged rats. J Gerontol A Biol Sci Med Sci. 2010;65:236-241.
146. Reynolds SL, Haley WE, Kozlenko N. The impact of depressive symptoms and chronic diseases on active life expectancy in older Americans. Am J Geriatr Psychiatry. 2008;16:425-432.
147. Chen CN, Brown-Borg HM, Rakoczy SG, Thompson LV. Muscle disuse: adaptation of antioxidant systems is age dependent. J Gerontol A Biol Sci Med Sci. 2008;63:461-466.
148. Young FG. Permanent experimental diabetes produced by pituitary (anterior lobe) injections. Lancet. 1937;2:372-374.
149. Houssay BA. Carbohydrate metabolism. N Engl J Med. 1936;214:971-986.
150. Valcarcel-Ares MN, Gautam T, Warrington JP, et al. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J Gerontol A Biol Sci Med Sci. 2011. In press.
151. Panici JA, Harper JM, Miller RA, Bartke A, Spong A, Masternak MM. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. FASEB J. 2010;24:5073-5079.